Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the combination of pemetrexed and carboplatin with the combination of docetaxel and carboplatin in terms of survival without Grade 3 or 4 toxicity in previously untreated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Carboplatin; Docetaxel; Pemetrexed

Criteria

Inclusion Criteria:

• Patient with locally advanced or metastatic (Stage IIIB/IV) NCSLC with no prior chemotherapy for advanced disease or molecular target treatment

• Easter Cooperative Oncology Group (ECOG) performance status 0 to 2

• Estimated life expectancy of at least 8 weeks

Exclusion Criteria:

• Known or suspected brain metastases

• Concurrent administration of any other tumor therapy

• Serious concomitant disorders

• Pregnancy or breast feeding

• Inability or unwillingness to take folic acid or vitamin B12 supplementation